tradingkey.logo
tradingkey.logo
Search

Grail Inc

GRAL
Add to Watchlist
61.260USD
-0.380-0.62%
Close 05/11, 16:00ETQuotes delayed by 15 min
2.52BMarket Cap
LossP/E TTM

More Details of Grail Inc Company

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Grail Inc Info

Ticker SymbolGRAL
Company nameGrail Inc
IPO dateJun 12, 2024
CEORagusa (Robert)
Number of employees1000
Security typeOrdinary Share
Fiscal year-endJun 12
Address1525 O'brien Drive
CityMENLO PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94025
Phone18336942553
Websitehttps://grail.com/
Ticker SymbolGRAL
IPO dateJun 12, 2024
CEORagusa (Robert)

Company Executives of Grail Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
103.89K
+7.89%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
30.93K
+59.09%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
28.39K
+63.60%
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
16.43K
-314.97%
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--
Mr. Andy Partridge
Mr. Andy Partridge
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
103.89K
+7.89%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
30.93K
+59.09%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
28.39K
+63.60%
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
16.43K
-314.97%
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
By BusinessUSD
Name
Revenue
Proportion
Screening
138.60M
94.18%
Development Services
8.57M
5.82%
By RegionUSD
Name
Revenue
Proportion
United States
137.09M
93.15%
International
10.08M
6.85%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Screening
138.60M
94.18%
Development Services
8.57M
5.82%

Shareholding Stats

Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.80%
Farallon Capital Management, L.L.C.
5.46%
Baker Bros. Advisors LP
4.86%
PRIMECAP Management Company
4.28%
State Street Investment Management (US)
4.26%
Other
75.34%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.80%
Farallon Capital Management, L.L.C.
5.46%
Baker Bros. Advisors LP
4.86%
PRIMECAP Management Company
4.28%
State Street Investment Management (US)
4.26%
Other
75.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor
26.13%
Investment Advisor/Hedge Fund
21.44%
Hedge Fund
16.74%
Research Firm
7.21%
Corporation
3.03%
Individual Investor
1.69%
Venture Capital
1.07%
Private Equity
0.55%
Pension Fund
0.54%
Other
21.59%

Institutional Shareholding

Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
1071
33.74M
78.63%
+1.76M
2025Q4
993
25.86M
66.33%
-6.45M
2025Q3
934
24.89M
69.05%
-6.05M
2025Q2
874
30.08M
83.61%
-1.68M
2025Q1
859
29.51M
82.19%
-2.62M
2024Q4
810
31.24M
92.16%
+4.27M
2024Q3
748
27.13M
81.56%
+4.49M
2024Q2
646
27.14M
86.18%
+27.14M
2024Q1
2
135.00
0.00%
+135.00

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
2.49M
6.07%
+368.34K
+17.35%
Dec 31, 2025
Farallon Capital Management, L.L.C.
2.34M
5.71%
+734.02K
+45.63%
Dec 31, 2025
Baker Bros. Advisors LP
2.09M
5.08%
+455.21K
+27.92%
Dec 31, 2025
PRIMECAP Management Company
1.84M
4.48%
-182.26K
-9.02%
Dec 31, 2025
State Street Investment Management (US)
1.83M
4.46%
+510.55K
+38.77%
Dec 31, 2025
Illumina Inc
1.30M
3.17%
-2.20M
-62.82%
Dec 31, 2025
CRCM L.P.
1.07M
2.61%
-728.28K
-40.45%
Dec 31, 2025
Arbiter Partners Capital Management, LLC
1.04M
2.52%
-300.00
-0.03%
Dec 31, 2025
Deep Track Capital LP
1.02M
2.49%
+1.02M
--
Dec 31, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ROBO Global Healthcare Technology & Innovation ETF
3.75%
Clough Select Equity ETF
2.7%
Clough Hedged Equity ETF
2.53%
Franklin Genomic Advancements ETF
2.49%
First Trust Small Cap Growth AlphaDEX Fund
1.08%
State Street SPDR S&P Biotech ETF
0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
0.71%
Direxion Daily S&P Biotech Bull 3X Shares
0.59%
ProShares Ultra Nasdaq Biotechnology
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.42%
View more
ROBO Global Healthcare Technology & Innovation ETF
Proportion3.75%
Clough Select Equity ETF
Proportion2.7%
Clough Hedged Equity ETF
Proportion2.53%
Franklin Genomic Advancements ETF
Proportion2.49%
First Trust Small Cap Growth AlphaDEX Fund
Proportion1.08%
State Street SPDR S&P Biotech ETF
Proportion0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.71%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.59%
ProShares Ultra Nasdaq Biotechnology
Proportion0.48%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.42%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI